BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Naproxen Sodium (Aleve, BAY117031)
Drug: Acetaminophen ER
Drug: Celecoxib
Drug: Placebo

First Posted Date: 2018-06-27

Last Posted Date: 2020-06-19

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT03570554

Locations: 🇺🇸
Radiant Research, Inc., San Antonio, Texas, United States

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Phase 4

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2018-06-21

Last Posted Date: 2024-12-03

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT03564938

Locations: 🇮🇳
Apollo Research Foundation, Hyderabad, Andhra Pradesh, India
🇮🇳
Sir Ganga Ram Hospital, New-Delhi, Delhi, India
🇮🇳
Shalby Hospital, Ahmedabad, Gujarat, India

and more 10 locations

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Phenprocoumon
Drug: Apixaban
Drug: Edoxaban

First Posted Date: 2018-06-20

Last Posted Date: 2020-11-27

Lead Sponsor: Bayer

Target Recruit Count: 64920

Registration Number: NCT03563937

Locations: 🇩🇪
Many Locations, Multiple Locations, Germany

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: Radium-223 (Xofigo, Bay88-8223)

First Posted Date: 2018-06-20

Last Posted Date: 2020-05-20

Lead Sponsor: Bayer

Target Recruit Count: 164

Registration Number: NCT03563014

Locations: 🇧🇪
Many Locations, Multiple Locations, Belgium

A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components

Phase 2

Completed

Conditions: Contraception

Interventions: Drug: BAY98-7443
Drug: Levonogestrel (Skyla, BAY86-5028)

First Posted Date: 2018-06-19

Last Posted Date: 2019-08-12

Lead Sponsor: Bayer

Target Recruit Count: 177

Registration Number: NCT03562624

Locations: 🇩🇪
Frauenarztpraxis Dr. Wetzel, Blankenburg, Sachsen-Anhalt, Germany
🇩🇪
Nuvisan GmbH, Neu-Ulm, Bayern, Germany
🇬🇧
PAREXEL International Early Phase Clinical Unit (London), Harrow, United Kingdom

and more 4 locations

An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

Interventions: Device: BPI 1000013 (Dr Scholls Insole)

First Posted Date: 2018-06-14

Last Posted Date: 2018-11-23

Lead Sponsor: Bayer

Target Recruit Count: 89

Registration Number: NCT03556787

Locations: 🇺🇸
Focus & Testing, Inc., Calabasas, California, United States
🇺🇸
The Wolf Group, Cincinnati, Ohio, United States

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

Phase 2

Completed

Conditions: Chronic Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
Drug: Placebo

First Posted Date: 2018-06-06

Last Posted Date: 2021-01-06

Lead Sponsor: Bayer

Target Recruit Count: 789

Registration Number: NCT03547583

Locations: 🇺🇸
Capitol Interventional Cardiology, Carmichael, California, United States
🇺🇸
Cardiovascular and Vein Center of Florida, Bradenton, Florida, United States
🇺🇸
Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States

and more 173 locations

Maintenance Treatment of Renal Anemia in Dialysis Subjects

Phase 3

Completed

Conditions: Renal Insufficiency, Chronic
Anemia

Interventions: Drug: Molidustat (BAY85-3934)
Drug: Darbepoetin alfa
Drug: Placebo of Molidustat (BAY85-3934)
Drug: Placebo of Darbepoetin alfa

First Posted Date: 2018-06-01

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 229

Registration Number: NCT03543657

Locations: 🇯🇵
Chibune Clinic, Osaka, Japan
🇯🇵
Maruko Central Hospital, Ueda, Nagano, Japan
🇯🇵
Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan

and more 50 locations

BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: BAY1830839

First Posted Date: 2018-05-30

Last Posted Date: 2020-08-05

Lead Sponsor: Bayer

Target Recruit Count: 64

Registration Number: NCT03540615

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients

Phase 1

Completed

Conditions: Cough

Interventions: Drug: BAY1902607
Drug: Matching placebo
Drug: Midazolam

First Posted Date: 2018-05-24

Last Posted Date: 2021-02-10

Lead Sponsor: Bayer

Target Recruit Count: 59

Registration Number: NCT03535168

Locations: 🇳🇱
Catharina Ziekenhuis, Eindhoven, Noord-Brabant, Netherlands
🇳🇱
Isala, Zwolle, Netherlands
🇬🇧
Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy